Prosecution Insights
Last updated: April 19, 2026

Examiner: MCGARRY, SEAN

Tech Center 1600 • Art Units: 1635 1674

This examiner grants 71% of resolved cases

Performance Statistics

71.2%
Allow Rate
+11.2% vs TC avg
883
Total Applications
+16.6%
Interview Lift
995
Avg Prosecution Days
Based on 874 resolved cases, 2023–2026

Rejection Statute Breakdown

3.9%
§101 Eligibility
18.2%
§102 Novelty
33.3%
§103 Obviousness
23.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17769322 Treatment of Airway Conditions by Modulation of MiR200 Family MicroRNAs Non-Final OA The Regents of the University of California
18299509 MODULATION OF GENE EXPRESSION AND SCREENING FOR DEREGULATED PROTEIN EXPRESSION Non-Final OA University of Southampton
18158290 COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION Non-Final OA Ionis Pharmaceuticals, Inc.
17481679 COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION Non-Final OA Ionis Pharmaceuticals, Inc.
18207609 MRNA THERAPY FOR POMPE DISEASE Final Rejection Translate Bio, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month